Your browser doesn't support javascript.
loading
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Bonnevaux, Hélène; Guerif, Stephane; Albrecht, Jana; Jouannot, Erwan; De Gallier, Thibaud; Beil, Christian; Lange, Christian; Leuschner, Wulf Dirk; Schneider, Marion; Lemoine, Cendrine; Caron, Anne; Amara, Céline; Barrière, Cédric; Siavellis, Justine; Bardet, Valérie; Luna, Ernesto; Agrawal, Pankaj; Drake, Donald R; Rao, Ercole; Wonerow, Peter; Carrez, Chantal; Blanc, Véronique; Hsu, Karl; Wiederschain, Dmitri; Fraenkel, Paula G; Virone-Oddos, Angéla.
Afiliação
  • Bonnevaux H; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Guerif S; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Albrecht J; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Jouannot E; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • De Gallier T; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Beil C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Lange C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Leuschner WD; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Schneider M; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Lemoine C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Caron A; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Amara C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Barrière C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Siavellis J; Hopitaux Universitaires Paris Ile De France Ouest, Université Versailles Saint Quentin, Paris, France.
  • Bardet V; Hopitaux Universitaires Paris Ile De France Ouest, Université Versailles Saint Quentin, Paris, France.
  • Luna E; Sanofi Pasteur VaxDesign, Orlando, FL, USA.
  • Agrawal P; Sanofi Pasteur VaxDesign, Orlando, FL, USA.
  • Drake DR; Sanofi Pasteur VaxDesign, Orlando, FL, USA.
  • Rao E; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Wonerow P; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Carrez C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Blanc V; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Hsu K; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Wiederschain D; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Fraenkel PG; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
  • Virone-Oddos A; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.
Oncoimmunology ; 10(1): 1945803, 2021.
Article em En | MEDLINE | ID: mdl-34484869
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Anticorpos Biespecíficos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Anticorpos Biespecíficos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article